Last update 11 Jun 2025

Hemopexin (CSL Behring)

Overview

Basic Info

Drug Type
Protein drugs
Synonyms
CSL-889
Target
Action
modulators
Mechanism
HPX modulators(hemopexin modulators)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia, Sickle CellPhase 3
United States
11 Jul 2025
Vaso-occlusive crisisPhase 3
United States
11 Jul 2025
Acute Chest SyndromePhase 1
United States
20 May 2021
Acute Chest SyndromePhase 1
Netherlands
20 May 2021
Acute Chest SyndromePhase 1
United Kingdom
20 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
28
(Part A)
kbtxwrdfyu(porjdozctu) = Seventy treatment emergent adverse events (TEAEs) were reported in 22 subjects (51 mild, 18 moderate and 1severe). Number or severity of TEAEs did not increase with dose or VOC status. The most common TEAEs were sickle cell anemia with crisis (29% of subjects, all ≥1 week after CSL889) and headache (17%). buqiotmhug (rdjycoasbg )
Positive
14 May 2024
(Part B)
Not Applicable
-
(HPX +/+)
flmnszqazt(dzozszhqgm) = soljissnkc xfsqrryxtm (pozgivmcdq )
-
23 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free